Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Indications for Treatment.
10.4166/kjg.2016.67.3.123
- Author:
Kyung Ah KIM
1
Author Information
1. Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea. kakim@ilsanpaik.ac.kr
- Publication Type:Review
- Keywords:
Hepatitis C;
Direct acting antiviral agents;
Indication;
Therapeutics;
Guideline
- MeSH:
Antiviral Agents/*therapeutic use;
Drug Therapy, Combination;
Hepatitis C/*drug therapy;
Humans;
Interferon-alpha/therapeutic use;
Liver Cirrhosis/complications;
Liver Neoplasms/complications;
Liver Transplantation;
Practice Guidelines as Topic;
Republic of Korea;
Ribavirin/therapeutic use
- From:The Korean Journal of Gastroenterology
2016;67(3):123-126
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The landscape of treatment for HCV infection has evolved substantially with the advent of highly effective direct-acting antiviral agents (DAA). The Korean Association for the Study of the Liver updated guideline for managemnt of hepatitis C in accordance with the introduction of DAA into practice in late 2015. Due to high effectiveness and few side effects of DAA, indications for treatment has been widened to include patients who had been contraindicated for the combination treatment of peginterferon-α and ribavirin, i.e. decompensated cirrhosis and pre- and post-liver transplant setting. As succeesul treatment of HCV can reduce complications of cirrhosis, development of hepatocelluar carcinoma and liver-related mortality, and improve extrahepatic manifestions, all HCV-infected patients with no contraindication should be considered for treatment. Considering the risk for morbidity and mortality and benefit of treatment, patients with advanced fibrosis ≥F3 including compensated and decompensated cirrhosis, those in the pre- and post-tranplasnt setting, and those with severe extrahepatic manifestations including HCV-related mixed cryoglobulinemia and glomerulonephritis should be given priority for treatment.
